Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth
The rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust.
HERZLIYA, Israel and CALGARY, AB, July 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), B.I. Sky Global Ltd., the consumer wellness subsidiary of Innocan Pharma Corporation, is proud to announce that its flagship skincare brand, Valitic, has surpassed 2 million trusted customers, marking a significant milestone in the Company's continued expansion in the beauty and personal care market.
Built on a commitment to developing innovative, consumer-focused skincare products, Valitic has experienced strong growth across leading e-commerce platforms, earning the confidence of millions of customers through high-quality formulations and consistent product performance.
This a remarkable achievement and validates our strategy of combining innovative product development with data-driven digital marketing," said Roni Kamhi, CEO of B.I. Sky Global Ltd. "Consumer trust is earned one customer at a time. This milestone reflects the quality of our products, the dedication of our team, and our relentless focus on understanding and meeting evolving consumer needs. "
Iris Bincovich, Chief Executive Officer of Innocan Pharma Corporation, added: "This milestone demonstrates the successful execution of our growth strategy. We believe this achievement marks an important step toward creating sustainable long-term value for our shareholders.
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, LPT-CBD's potential to improve treatment and overall patient experience in chronic pain management and consumer growth of the Valitic brand, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
SOURCE Innocan Pharma Corporation
Share this article